Raptor to advance neurodegenerative disorder drug in registration study

(Reuters) - Raptor Pharmaceutical Corp reported promising data from a mid-stage trial of its experimental neurodegenerative disorder drug, codenamed RP103, and said it would advance it in a registration study.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro